Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven ...

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail ...

Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

In this snippet from an executive virtual roundtable, Marcio Souza, CEO of Praxis Precision Medicines, discusses how he became CEO of Praxis during a pandemic and how he soon thereafter took the ...

The pharmaceutical industry sits on a treasure trove of data, brimming with the potential to revolutionize drug development, enhance patient care, and optimize commercial strategies. Yet, this vast ...

An R&D project has shown that the solubility and dissolution characteristics for Itraconazole can be improved by helping them to maintain an amorphous state after spray drying with selected ...

From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech ...